Improving outcomes for neurofibromatosis 1-associated brain tumors (Q38344456)

2 September 2017

1 reference

title

Improving outcomes for neurofibromatosis 1-associated brain tumors (English)

1 reference

2 September 2017

publication date

5 February 2015

1 reference

Expert Review of Anticancer Therapy

2 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25652347%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25652347%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25652347%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

415-423

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25652347%20AND%20SRC:MED&resulttype=core&format=json

Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Use of "unidentified bright objects" on MRI for diagnosis of neurofibromatosis 1 in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Neurofibromatosis type 1 and high-grade tumors of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

The architecture of optic nerve gliomas with and without neurofibromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Functional outcome measures for NF1-associated optic pathway glioma clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Handheld optical coherence tomography during sedation in young children with optic pathway gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Precocious puberty in children with neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Neurofibromatosis type 1: brain stem tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Chemotherapy for brain stem gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Cerebellar gliomas in children with NF1: pathology and surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Outcome of secondary high-grade glioma in children previously treated for a malignant condition: a study of the Canadian Pediatric Brain Tumour Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Pten haploinsufficiency accelerates formation of high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

A restricted cell population propagates glioblastoma growth after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

21 January 2018

Reply: To PMID 24375753.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

Optimizing biologically targeted clinical trials for neurofibromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1009043

10.1586/14737140.2015.1009043

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25652347%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference